:Quinupramine

{{short description|Tricyclic antidepressant}}

{{Drugbox

| IUPAC_name = (±)-11-quinuclidin-3-yl-5,6-dihydrobenzo[b][1]benzazepine

| image = Quinupramine.svg

| tradename =

| pregnancy_category =

| legal_status = Rx-only

| routes_of_administration = Oral

| bioavailability =

| metabolism =

| elimination_half-life = 33 hours

| excretion =

| CAS_number = 31721-17-2

| ATC_prefix = N06

| ATC_suffix = AA23

| PubChem = 93154

| ChemSpiderID = 84098

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 29O61HFF4L

| KEGG = D07336

| C=21 | H=24 | N=2

}}

Quinupramine (brand names Kevopril, Kinupril, Adeprim, Quinuprine) is a tricyclic antidepressant (TCA) used in Europe for the treatment of depression.{{cite book | author = Swiss Pharmaceutical Society | title = Index Nominum 2000: International Drug Directory (Book with CD-ROM) | publisher = Medpharm Scientific Publishers | location = Boca Raton | year = 2000 | page = 908 | isbn = 3-88763-075-0 | url = https://books.google.com/books?id=5GpcTQD_L2oC&q=quinupramine&pg=PA908}}{{cite book | vauthors = Vela JM, Buschmann H, Holenz J, Párraga A, Torrens A | title = Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application | publisher = Wiley-VCH | location = Weinheim | year = 2007 | page = 248 | isbn = 978-3-527-31058-6 | url = https://books.google.com/books?id=yXD4QA-Y_Z0C&q=quinupramine&pg=PA248}}

Pharmacologically, quinupramine acts in vitro as a strong muscarinic acetylcholine receptor antagonist (anticholinergic) and H₁ receptor antagonist (antihistamine), moderate 5-HT₂ receptor antagonist, and weak serotonin and norepinephrine reuptake inhibitor.{{cite journal | vauthors = Sakamoto H, Yokoyama N, Kohno S, Ohata K | title = Receptor binding profile of quinupramine, a new tricyclic antidepressant | journal = Japanese Journal of Pharmacology | volume = 36 | issue = 4 | pages = 455–460 | date = December 1984 | pmid = 6098759 | doi = 10.1254/jjp.36.455 | doi-access = free }} It has negligible affinity for the α₁-adrenergic, α₂-adrenergic, β-adrenergic, or D₂ receptor.

Clinically, quinupramine is reported to be stimulating similarly to imipramine, desipramine, and demexiptiline.{{cite book | vauthors = Kent A, Billiard M | title = Sleep: physiology, investigations, and medicine | publisher = Kluwer Academic/Plenum | location = New York | year = 2003 | page = 233 | isbn = 0-306-47406-9 | url = https://books.google.com/books?id=IorPrIY6dOYC&q=quinupramine&pg=PA233}} It can be inferred that its in vivo metabolites may have stronger effects on the reuptake of norepinephrine and/or serotonin than quinupramine itself.{{Citation needed|date=October 2014}}